Recap: Today's top stories from ASCO 2024 include updates on safety data about a myelofibrosis candidate, and record ...

At a STAT event, oncology leaders spoke of advances that are turning old ideas like antibody-drug conjugates into broadly ...

CHICAGO — The Food and Drug Administration’s top oncologist reiterated that the agency doesn’t want drugmakers applying for ...

Corbus, reporting on early trials of its antibody-drug conjugate, says it "seems to be clinically effective in bladder cancer ...

CHICAGO — People can be mightily reluctant to get a colonoscopy for reasons like cost, language barriers, or fear of what the ...

To encourage robust, good-faith discussion about issues raised in First Opinion, STAT publishes selected Letters to the ...

The Biden administration has significantly opened the door to drug treatment strategies that help reduce substance use, even ...

One data point makes new results on Pfizer's cancer drug Lorbrena quite eye-catching: It reduced disease progression by 81%.

After years of inertia, the field of research into the health effects of marijuana may be about to get a boost. Maybe.

The federal agency's clarification means hospitals, doctors and other providers don't have to track down and inform millions ...

Two late-stage trials showed an Ionis experimental therapy for hereditary angioedema benefitted patients — including those ...

The FDA approved Moderna’s vaccine to protect older adults against respiratory syncytial virus, or RSV, making this the ...